Molecular Partners AG Capital Reinvestment Ratio
Molecular Partners AG capital reinvestment ratio. Molecular Partners AG (MOLN) has a Capital Reinvestment Ratio of 0.00x as of March 2022, meaning it reinvests 0% of its operating cash flow (CHF163.56 Million) in capital expenditures (CHF380.00K). Check total reinvestment intensity of Molecular Partners AG to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Molecular Partners AG (2015–2022)
Capital reinvestment ratio of Molecular Partners AG from 2015 to 2022. This chart tracks Molecular Partners AG's Capital Reinvestment Ratio across 2 annual periods. Also explore net asset momentum of Molecular Partners AG to track the company's year-over-year net asset growth rate.
Molecular Partners AG Capital Reinvestment Ratio by Year (2015–2022)
Molecular Partners AG capital reinvestment ratio by year from 2015 to 2022. For the full cash flow conversion analysis, see MOLN cash flow metrics.
| Year | Reinvestment Ratio | Operating CF (CHF) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.01x | CHF118.57 Million | CHF1.42 Million | ▼ -77.2% |
| 2015 | 0.05x | CHF26.50 Million | CHF1.39 Million | — |